New hope for tough breast cancer: experimental combo challenges standard treatment
NCT ID NCT07040644
Summary
This study compares two different drug combinations for people with advanced triple-negative breast cancer who haven't had previous treatment. About 150 participants will receive either an experimental combination (sacituzumab govitecan plus toripalimab) or the current standard combination (toripalimab plus nab-paclitaxel). Researchers will track how long patients live without their cancer getting worse and monitor side effects to see which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.